Transaction Details

Anupam Rasayan India Limited has entered into a definitive agreement to acquire 43.3-48.2% equity stake in Bliss GVS Pharma Limited (NSE: BLISSGVS, BSE: 506197), an India-based pharmaceutical formulations company. The transaction includes a mandatory open offer to the public shareholders of Bliss GVS Pharma Limited.

Financing Structure

The total purchase consideration is being financed through:

  • Rs 300 Crores via Term Loan
  • Non-Controlling non-voting equity instrument for the balance amount

Strategic Rationale

As stated by Managing Director Mr. Anand Desai, the acquisition represents an important milestone in Anupam Rasayan's vision of building an integrated global life sciences and specialty pharmaceutical platform. The transaction will strategically strengthen presence across the pharmaceutical value chain from KSMs (Key Starting Materials) to finished dosage formulations.

Bliss GVS Pharma brings established capabilities in niche dosage forms, strong international footprint, differentiated brands, and expertise across multiple therapeutic segments. The combined platform aims to create a broader integrated and diversified pharmaceutical manufacturing ecosystem with deeper backward integration and enhanced global reach, particularly in European and American markets.

About Bliss GVS Pharma Limited

Bliss GVS Pharma Limited is an India-based pharmaceutical formulations company established in 1984 and listed on NSE and BSE. The company is engaged in development, manufacturing, marketing, and export of wide range of dosage forms including suppositories, pessaries, tablets, capsules, syrups, injectables, creams, and ointments.

Key attributes of Bliss GVS Pharma:

  • Strong presence across regulated and semi-regulated international markets, particularly in Africa, Asia, and Latin America
  • Global leadership in suppositories and pessaries with one of the largest product portfolios in this segment
  • Among few EU-GMP certified manufacturers in India for these dosage forms
  • Diversified portfolio of over 150 branded formulations across therapeutic areas including antimalarial, anti-fungal, anti-bacterial, anti-inflammatory, and women's healthcare
  • Key established brands: Lonart, P-Alaxin, Funbact, and Lofnac
  • Multiple manufacturing facilities in Maharashtra and Daman with approvals from US FDA, WHO-GMP and EU-GMP
  • Developed strong capabilities in niche dosage forms with expanding R&D, manufacturing, and international marketing footprint

Expected Synergies

The acquisition is expected to unlock significant synergies through:

  • Expanded product offerings
  • Stronger regulated market presence
  • Improved customer engagement
  • Accelerated innovation across regulated and semi-regulated markets
  • Operational efficiencies
  • Long-term value creation for all stakeholders

Effective Date

The press release is dated May 23, 2026, and the disclosure was filed on the same date.

#Tags #AnupamRasayan #BlissGVSPharma #Acquisition #OpenOffer #SEBIDisclosure #RegulatoryCompliance #M&A #Neutral